Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Zoetis Inc.
Zoetis Inc. News
Zoetis Inc. Quantitative Score
About Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Zoetis Inc. Earnings & Revenue
Zoetis Inc. Financials
Table Compare
Compare ZTS metrics with: | |||
---|---|---|---|
Earnings & Growth | ZTS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ZTS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ZTS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ZTS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Zoetis Inc. Income
Zoetis Inc. Balance Sheet
Zoetis Inc. Cash Flow
Zoetis Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Strong Buy |
Return on Assets | Strong Buy |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Zoetis Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 1.6710 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-09-04 | 0.432 | Quarterly |
2024-06-04 | 0.432 | Quarterly |
2024-03-01 | 0.432 | Quarterly |
2023-12-01 | 0.375 | Quarterly |
2023-09-01 | 0.375 | Quarterly |
Zoetis Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Zoetis Inc. Executives
Name | Role |
---|---|
Ms. Kristin C. Peck | Chief Executive Officer & Director |
Mr. Wetteny N. Joseph | Executive Vice President & Chief Financial Officer |
Ms. Wafaa Mamilli | EVice President, Chief Digital & Tech. Officer, Group President for China, Brazil and Preci. Animal Health |
Dr. Robert J. Polzer Ph.D. | Executive Vice President and President of Research & Development |
Mr. Nick Ashton | Executive Vice President and President of Global Manufacturing & Supply |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Ms. Kristin C. Peck | Chief Executive Officer & Director | Female | 1971 | 3.54M |
Mr. Wetteny N. Joseph | Executive Vice President & Chief Financial Officer | Male | 1972 | 1.6M |
Ms. Wafaa Mamilli | EVice President, Chief Digital & Tech. Officer, Group President for China, Brazil and Preci. Animal Health | Female | 1967 | 1.36M |
Dr. Robert J. Polzer Ph.D. | Executive Vice President and President of Research & Development | 1969 | 1.18M | |
Mr. Nick Ashton | Executive Vice President and President of Global Manufacturing & Supply | Male | 1973 | -- |
Zoetis Inc. Insider Trades
Date | 30 Sep |
Name | FULLER JULIE |
Role | Executive Vice President |
Transaction | Acquired |
Type | A-Award |
Shares | 2324 |
Date | 3 Sep |
Name | FULLER JULIE |
Role | Executive Vice President |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | 3 Sep |
Name | MCCALLISTER MICHAEL B |
Role | Director |
Transaction | Disposed |
Type | G-Gift |
Shares | 16854 |
Date | 31 Jul |
Name | Banque Soria Ester |
Role | Executive Vice President |
Transaction | Acquired |
Type | M-Exempt |
Shares | 895 |
Date | 31 Jul |
Name | Banque Soria Ester |
Role | Executive Vice President |
Transaction | Disposed |
Type | F-InKind |
Shares | 307 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
30 Sep | FULLER JULIE | Executive Vice President | Acquired | A-Award | 2324 |
3 Sep | FULLER JULIE | Executive Vice President | Disposed | 0 | |
3 Sep | MCCALLISTER MICHAEL B | Director | Disposed | G-Gift | 16854 |
31 Jul | Banque Soria Ester | Executive Vice President | Acquired | M-Exempt | 895 |
31 Jul | Banque Soria Ester | Executive Vice President | Disposed | F-InKind | 307 |